Nifedipine (Synonyms: 硝苯地平; BAY-a-1040)

目录号: HY-B0284 纯度: 99.90%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Nifedipine (BAY-a-1040) 是有效的钙离子通道 (calcium channel) 阻滞剂，常用于心肌功能不全的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Nifedipine Chemical Structure

CAS No. : 21829-25-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥700	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Nifedipine:

MCE 顾客使用本产品发表的 15 篇科研文献

Nifedipine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Calcium Channel 亚型特异性产品:

查看所有亚型

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: NIF	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
Calvarial osteoblast	EC₅₀	1.54 μM Compound: nifedipine	Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation after 21 days by alizarin red-S staining based spectrophotometric analysis Induction of mineralization in mouse calvarial osteoblasts assessed as increase of mineralized nodules formation after 21 days by alizarin red-S staining based spectrophotometric analysis	[PMID: 23214410]
CHO	IC₅₀	0.01 μM Compound: nifedipine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
CHO	IC₅₀	0.05 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in Chinese hamster ovary cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HCT-116	IC₅₀	> 100 μM Compound: NIF	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
HEK293	IC₅₀	0.022 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	0.055 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HEK293	IC₅₀	0.086 μM Compound: Nif	Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis Displacement of [3H]-PN200-110 from voltage-gated calcium channel subunit alpha Cav1.2a (unknown origin) expressed in HEK293 cells after 90 mins by liquid scintillation counting analysis	[PMID: 23586669]
HEK-293T	IC₅₀	1.5 μM Compound: Nifedipine	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	46 μM Compound: Nifedipine	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HepG2	IC₅₀	9.4 μM Compound: Nifedipine	Cytotoxicity against human HepG2 cells after 24 hrs by LDH release assay Cytotoxicity against human HepG2 cells after 24 hrs by LDH release assay	[PMID: 30554954]
L929	IC₅₀	6.1 μM Compound: 1	Inhibition of human Kv1.5 channel expressed in mouse L929 cells by EP voltage clamp technique Inhibition of human Kv1.5 channel expressed in mouse L929 cells by EP voltage clamp technique	[PMID: 19004630]
LLC-MK2	IC₅₀	101.75 μM Compound: Nifedipine	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
LLC-MK2	IC₅₀	588.73 μM Compound: Nifedipine	Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
MCF7	IC₅₀	> 100 μM Compound: NIF	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
MM1.S	IC₅₀	57.9 μM Compound: NIF	Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay	[PMID: 31673316]
SH-SY5Y	IC₅₀	1.35 μM Compound: nifedipine	Inhibition of human Cav1.3 channel in human SH-SY5Y cells assessed as 70 mM K+ induced calcium elevation compound treated 15 mins before stimulus by Fluo-4/AM assay Inhibition of human Cav1.3 channel in human SH-SY5Y cells assessed as 70 mM K+ induced calcium elevation compound treated 15 mins before stimulus by Fluo-4/AM assay	[PMID: 24754640]
SH-SY5Y	IC₅₀	22 μM Compound: Nifedipine	Inhibition of voltage-dependent L-type calcium channel in 70 mM K+-induced human SH-SY5Y cells assessed as blocking of depolarization-induced Ca2+ uptake by Fluo-4/AM dye based fluorescence microplate reader assay Inhibition of voltage-dependent L-type calcium channel in 70 mM K+-induced human SH-SY5Y cells assessed as blocking of depolarization-induced Ca2+ uptake by Fluo-4/AM dye based fluorescence microplate reader assay	[PMID: 31724859]
Ventricular myocyte	IC₅₀	0.05 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	0.26 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]
Ventricular myocyte	IC₅₀	0.3 μM Compound: Nifedipine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]

体外研究
(In Vitro)

Nifedipine (BAY-a-1040) (100 μM) 显著降低了 WKPT-0293 Cl.2 细胞的活力，Nifedipine (10 或 100 μM) 加 FAC 处理可显著降低细胞活力，但对照细胞与用 100 μM FAC 或 1 和 10 μM Nifedipine 处理的细胞之间的活力没有显著差异。Nifedipine (BAY-a-1040) (1、10 或 100 μM) 显著提高 WKPT-0293 Cl.2 细胞中的铁含量。Nifedipine 处理还会增加 WKPT-0293 Cl.2 细胞中 TfR1、DMT1+IRE 和 DMT1-IRE 的表达。此外，Nifedipine (100 μM) 和 FAC (100 μM) 联合治疗可增加 WKPT-0293 Cl.2 细胞中的 TfR1、DMT1+IRE 和 DMT1-IRE 表达^[2]。
Nifedipine 和利托君在中等浓度范围内产生的收缩力抑制作用显著强于单独使用每种药物。Nifedipine 和硝酸甘油或 Nifedipine加阿托西班的组合产生的抑制作用显著强于单独使用硝酸甘油或阿托西班，但不大于 Nifedipine。Nifedipine 加 NS-1619（Ca²⁺ 激活的 K⁺ [BKCa] 通道开放剂）的组合可降低每种药物的抑制作用^[3]。
Nifedipine (BAY-a-1040) (2 μM) 显著抑制辣椒炭疽菌菌丝生长和孢子形成。Nifedipine (BAY-a-1040) 诱导的菌丝生长抑制是钙依赖性的。Nifedipine (0.5 μM) 以钙依赖性方式增加辣椒炭疽菌对 H₂O₂ 的敏感性^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

在接受 Nifedipine (BAY-a-1040) (50 mg/kg) 和 CsA 治疗的大鼠中，第 4 周结束时 BL 尺寸 (BLi 和 BLk)、MD 尺寸 (MDk) 和垂直尺寸 (VHi 和 VHk) 均显著增加 (P < 0.05)^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

346.33

Formula

C₁₇H₁₈N₂O₆

CAS 号

21829-25-4

性状

固体

颜色

Light yellow to yellow

中文名称

硝苯地平；心痛定；硝苯吡啶；硝苯啶

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (288.74 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8874 mL	14.4371 mL	28.8742 mL
5 mM	0.5775 mL	2.8874 mL	5.7748 mL
10 mM	0.2887 mL	1.4437 mL	2.8874 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.22 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.90%

选择批次：

Data Sheet (654 KB) SDS (419 KB)

COA (296 KB) HNMR (241 KB) RP-HPLC (243 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Ratre MS, et al. Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats. J Indian Soc Periodontol. 2016 Jul-Aug;20(4):396-401. [Content Brief]

[2]. Carvajal JA, et al. The Synergic In Vitro Tocolytic Effect of Nifedipine Plus Ritodrine on Human Myometrial Contractility. Reprod Sci. 2017 Apr;24(4):635-640. [Content Brief]

[3]. Yu SS, et al. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60 [Content Brief]

[4]. Liu P, et al. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. [Content Brief]

Cell Assay ^[2]	Cell viability is assessed using an MTT assay. Briefly, a total of 25 μL MTT (1 g/L in PBS) is added to each well before incubation is conducted at 37°C for 4 h. The assay is stopped by the addition of a 100 μL lysis buffer (20% SDS in 50% N’Ndimethylformamide, pH 4.7). Optical density (OD) is measured at the 570 nm wavelength by the use of an ELX-800 microplate assay reader and the results are expressed as a percentage of the absorbance measured in the control cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	All the 30 rats are randomLy distributed into three equal groups of ten animals each. Group 1 (control) receive olive oil for the 8 weeks. Group 2 and Group 3 receive a combination of CsA (30 mg/kg body weight) and Nf (50 mg/kg body weight) in olive oil for 8 weeks. In Group 3 rats, Azi (10 mg/kg body weight) is added to this regimen, in the 5th week. The total study period is 8 weeks. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Ratre MS, et al. Effect of azithromycin on gingival overgrowth induced by cyclosporine A + nifedipine combination therapy: A morphometric analysis in rats. J Indian Soc Periodontol. 2016 Jul-Aug;20(4):396-401. [Content Brief] [2]. Carvajal JA, et al. The Synergic In Vitro Tocolytic Effect of Nifedipine Plus Ritodrine on Human Myometrial Contractility. Reprod Sci. 2017 Apr;24(4):635-640. [Content Brief] [3]. Yu SS, et al. Nifedipine Increases Iron Content in WKPT-0293 Cl.2 Cells via Up-Regulating Iron Influx Proteins. Front Pharmacol. 2017 Feb 13;8:60 [Content Brief] [4]. Liu P, et al. The L-type Ca(2+) Channel Blocker Nifedipine Inhibits Mycelial Growth, Sporulation, and Virulence of Phytophthora capsici. Front Microbiol. 2016 Aug 4;7:1236. [Content Brief]

Nifedipine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8874 mL	14.4371 mL	28.8742 mL	72.1855 mL
	5 mM	0.5775 mL	2.8874 mL	5.7748 mL	14.4371 mL
	10 mM	0.2887 mL	1.4437 mL	2.8874 mL	7.2185 mL
	15 mM	0.1925 mL	0.9625 mL	1.9249 mL	4.8124 mL
	20 mM	0.1444 mL	0.7219 mL	1.4437 mL	3.6093 mL
	25 mM	0.1155 mL	0.5775 mL	1.1550 mL	2.8874 mL
	30 mM	0.0962 mL	0.4812 mL	0.9625 mL	2.4062 mL
	40 mM	0.0722 mL	0.3609 mL	0.7219 mL	1.8046 mL
	50 mM	0.0577 mL	0.2887 mL	0.5775 mL	1.4437 mL
	60 mM	0.0481 mL	0.2406 mL	0.4812 mL	1.2031 mL
	80 mM	0.0361 mL	0.1805 mL	0.3609 mL	0.9023 mL
	100 mM	0.0289 mL	0.1444 mL	0.2887 mL	0.7219 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nifedipine21829-25-4BAY-a-1040硝苯地平心痛定硝苯吡啶硝苯啶Calcium ChannelAutophagyCa2+ channelsCa channelsInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Nifedipine (Synonyms: 硝苯地平; BAY-a-1040)

Customer Review

Other Forms of Nifedipine:

MCE 顾客使用本产品发表的 15 篇科研文献

Nifedipine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Calcium Channel 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Nifedipine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Nifedipine (Synonyms: 硝苯地平; BAY-a-1040)

Customer Review

Other Forms of Nifedipine:

Nifedipine 相关抗体

MCE 顾客使用本产品发表的 15 篇科研文献

Nifedipine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Calcium Channel 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Nifedipine 相关抗体:

摩尔计算器

稀释计算器

Nifedipine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z